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Background: Cystic fibrosis (CF) is a genetic disease characterized by complex polymicrobial communities within
the lower respiratory tract. S. pneumoniae, while a well-defined pathogen in the general population, has rarely been
identified in CF. Furthermore, prevalence studies on Pneumococcus in CF have predominantly focused on the infant
and pediatric populations, and outcome data is lacking.
Methods: Through a review of our comprehensive clinical and microbiologic database from a single adult CF
center in Canada from 1978–2013 we sought to determine the incidence, prevalence, serotype and clinical impact
of Pneumococcus in adults with CF.
Results: Only fifteen of 318 adult CF patients (5%) were ever found to have transient Pneumococcus colonization,
and none developed persistent infection although length of carriage varied. As all isolates were stored, capsular
serotyping could be performed using a multiplex PCR panel. Capsular serotyping revealed a varied distribution of
several serotypes within these isolates. Lung function testing at time of incident Pneumococcus isolation was
compared with values before and after isolation and showed no significant reduction in spirometry values, nor was
there an increased need for rescue antibacterial therapy.
Conclusion: Within our center, incident Pneumococcus infection is neither common, associated with a
disproportionate clinical deterioration nor results in chronic infection.
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Streptococcus pneumoniae is an important respiratory
pathogen that has been implicated in several respira-
tory diseases including otitis media, pneumonia and si-
nusitis [1]. The prevalence of pneumococcal nasal-
pharyngeal asymptomatic colonization in the healthy
adult population has been estimated to be at 20-50%
[2]. Isolation of Pneumococcus in CF has been pre-
dominantly studied in infants and young children [1,3].
Several studies have addressed the pathogenic potential
of Pneumococcus in CF and have found increased* Correspondence: mdparkin@ucalgary.ca
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unless otherwise stated.biofilm formation, increased antibiotic resistance [4]
and the isolation of this species during acute exacerba-
tion [1]. Studies on prevalence within adult CF patients
are limited; with one group finding ten percent of CF
patients had cultivatable isolates from routine sputum
samples during periods of clinical stability when spe-
cifically sought using enhanced culture techniques [2].
The impact of isolating Pneumococcus from sputum
on short and long term CF disease progression, how-
ever, is unknown.
The objectives of this study were to do a retrospective
longitudinal study of adult CF patients to assess Pneumo-
coccus incidence and prevalence as determined by routine
culture practices. Clinical impact of infection was evaluated
by comparing requirement for antibacterial therapy andal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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phenotypic characterization was performed including anti-
biotic susceptibility and capsular serotypes of the pneumo-
cocci isolates to assess distribution within this cohort of
adult CF patients.
Methods
A retrospective audit was performed on the Adult Cystic
Fibrosis Clinic of Southern Alberta, Canada’s compre-
hensive sputum biobank. This prospectively collected
and maintained biobank includes frozen stock of every
bacterial isolate ever identified, from every clinical en-
counter between 1978–2013. Inclusion of patients into
this study was dependent on a diagnosis of CF, and the
confirmation of positive culture(s) of S. pneumoniae
from any sputum sample done routinely at quarterly
clinic visits and during periods of exacerbation. Corre-
sponding clinical information was collected through de-
tailed chart review including baseline demographic
details, and the clinical course before and following iso-
lation of Pneumococcus. Differences for percent pre-
dicted FEV1 (forced expiratory volume in one second)
and FVC (functional vital capacity) lung function tests
were assessed using the Student’s unpaired t-test. This
study complies with the University of Calgary Conjoint
Health Research Ethics Board (CHREB E-23087).
Sputum samples collected in real time were mixed with
equal volumes of dithiothreitol (DTT, Sputolysin, EMD
Millipore Billerica, MA) and vigorously vortexed. Samples
were then serial diluted in DTT to a final dilution of 10−5.
Samples diluted at 10−3 and 10−5 were then plated on rou-
tine CF media including: Columbia Blood Agar (CBA),
MacConkey (MAC), Chocolate Agar (CHOC), Mannitol
Salt Agar (MSA) and in the later years Burkholderia cepacia
agar. S. pneumoniae were identified through standard ap-
proaches including flat, centrally depressed alpha-hemolytic
colonies on CBA/CHOC, which were Gram positive diplo-
coccoid, catalase-negative, Optochin sensitive (generally)
and bile salt soluble. Isolates were frozen in skim milk
stocks and maintained indefinitely at −80°C [5,6].
In 2014, S. pneumoniae isolates cataloged at any time
point from the biobank were then targeted and subbed
out from frozen stock and incubated in 5% CO2 at 37°C
for 48–72 hours and their identity re-confirmed. DNA
was extracted from isolates using boiling preparation
where colonies were re-suspended in 50 ul of ddH20,
boiled for 15 minutes and then centrifuged at
13,000 rpm for 10 minutes. Capsular serotyping PCR
was performed following the protocol described by Jour-
dain, et al. to screen for 30 classical S. pneumoniae col-
onizing serotypes [7]. A positive control of genomic
DNA from S. pneumoniae strain ATCC 6303 was used
alongside the internal cps loci within the multiplex PCR
for comparison. Each PCR reaction was run on twoseparate occasions to ensure accuracy. Susceptibility
testing was performed in real time to penicillin and
those samples recovered had susceptibility testing to
other common anti-Pneumococcal agents as well as
those antibiotics commonly used in CF, using the Kirby-
Bauer method as per the Clinical and Laboratory Stan-
dards Institute (CLSI) [8].
Results
During the 34 years assessed only 27 S. pneumoniae iso-
lates were identified from the 33,166 (0.08%) bacterial
isolates collected from expectorated sputum samples
from 318 patients in our biobank (Table 1). All isolates
were cultured from sputum in real time at colony form-
ing units (CFU) ranging from 104-107/ml (Table 2). No
invasive isolates were identified. These were from 15 pa-
tients; 10 males and 5 females with a median age of 28.0
(IQR (inter-quartile range) 23, 30) years at time of first
isolation. 11/15 of the patients were pancreatic insuffi-
cient and 67% 10/15 also had a major CF co-morbidity.
Co-morbidities included CF related diabetes (3/15),
arthropathy (3/15), liver and biliary problems (12/15)
and sinonasal manifestations (5/15). Interestingly, one-
third of the patients were chronic smokers. The median
(IQR) for baseline FEV1 was 75.5% predicted (62.5, 105.5)
and for FVC was 82.6% predicted (71.5, 112.5). Baseline
chronic microbial pathogens included P. aeruginosa (12/
15), S. aureus (7/12), H. influenzae (4/15) and Burkholderia
cepacia complex (2/15). 8/15 of the patients had co-
infection with two or more of the principal pathogens listed
above. None of the samples were from patients who had
previously undergone lung transplantation.
Twelve patients were at a routine clinic visit at the
time of sputum collection and subsequent Pneumococ-
cus isolation. Samples from three patients were taken at
time of hospitalization or during self-reported acute re-
ductions in health. Only two patients had chest imaging
done at time of sputum collection, and both showed pul-
monary infiltrates. Six patients had recurrent Pneumo-
coccus isolation, which was discontinuous over a period
of time ranging for several months, although none devel-
oped chronic infection. One patient had two separate in-
fection periods where different strains of Pneumococcus
were cultured a decade apart. Of note, 10 patients did
report flu-like symptoms prior to time of Pneumococcus
isolation (ranging from one week to five weeks) that
consisted of dyspnea (7/10), lethargy (100%), increased
sputum production (100%), hemoptysis (20%), and
weight loss (40%) from prior clinic visit. Several of the
patients with flu-like symptoms also had confirmed viral
titers preceding or at time of S. pneumoniae isolation
and were obtained during periods of acute exacerbation
(patient 2 with influenza A, patient 3 with influenza B
and patient 10 with influenza A and parainfluenza). No
Table 1 Adult cystic fibrosis patient demographics from those with isolated Pneumococcus cultures
















1 30 M M1101K M1101K 21.87 1.62 (35) 0.76 (20) N N N PA, SA, HI, Bcc
2 23 M F508del M1101K 16.05 3.29 (61) 0.94 (20) N N Liver disease PA, SA
3 30 F F508del P67L 32.03 N/A N/A Y Y N SA
4 28 M F508del F508del 18.23 3.75 (68) 2.42 (54) N N Sinus PA, Bcc
5 29 F F508del F508del 15.58 2.06 (53) 1.08 (32) N N CFRD, Sinus PA
6 24 M F508del D110H 24.38 7.57 (140) 5.98 (128) Y Y N HI
7 24 M F508del F508del 16.20 3.77 (73) 1.4 (32) Y N Sinus PA
8 30 M 3659delC 394delTT 18.79 3.95 (75) 1.80 (41) N Y Liver disease PA
9 28 M F508del F508del 21.20 6.1 (117) 4.3 (100) N N N PA, SA
10 23 M F508del G551D 20.1 5.08 (88) 3.55 (74) N N Sinus PA, SA
11 30 F F508del Unknown 19.0 1.58 (35) 1.08 (29) N N CFRD PA
12 18 M F508del G178R 20.8 4.04 (107) 3.01 (86) N Y Arthropathy,
Sinus
SA, HI
13 28 F F508del F508del 19.7 2.48 (73) 1.5 (51) N N N PA
14 40 F F508del F508del 25.4 4.45 (134) 3.08 (110) N Y CFRD,
Arthropathy
PA, HI
15 22 M F508del F508del 21.7 4.26 (85) 2.94 (68) N N Arthropathy PA, SA
aAge at time of first isolation of S. pneumoniae.
bBMI: body mass index.
cFVC: forced volume capacity, defined as an average of two values in the year preceding time of pneumococcus isolation.
dFEV1: forced expiratory volume, defined as an average of two values in the year preceding time of pneumococcus isolation.
ePA: P. aeruginosa, SA: S. aureus, HI: Haemophilus influenzae, Bcc: Burkholderia cepacia complex; chronicity as defined by repeated isolation of pathogen on at least
50% of cultures over the prior two years.
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bacterial therapies during the clinics from which Pneumo-
coccus was isolated to either those visits occurring in either
the year prior to its isolation [10/27 (37%) vs. 14/45 (31%),
relative risk (RR) 1.19 (CI 0.62-2.30), p = 0.62] or following
[10/27 (37%) vs. 21/45(46%), RR 0.8 (0.44-1.41), p = 0.47].
Of the 27 isolates, 18 were recoverable from frozen
stocks and their serotype confirmed (Table 2). Capsular
serotypes were performed on the 18 isolates with no pre-
dominance observed, rather a distribution of ten different
serotypes. Interestingly, three isolates could not be sero-
typed using multiplex PCR for the thirty most common
Pneumococcus serotypes [7] but did display the internal
cps control confirming Pneumococcus identification.
Among the patients with repeated isolates of Pneumococ-
cus, the serotypes identified were not homogenous and
were varied even within the same patient. Two patients (8
and 11) had the same Pneumococcus serotype of 23 F over
a one month period and 23B over a three month period.
Despite extensive chart review, Pneumococcus vaccination
records could only be found for one patient (9) with a
capsular serotype (23A) that was not included with the
23-valent Pneumococcus vaccine.
Detailed chart review observed that only two isolates
were resistant to penicillin upon original testing (7.7%).
Amongst the 18 recoverable isolates, additional antibioticsusceptibility testing was performed (Table 2). Four strains
(22%) were resistant to azithromycin, but none to clinda-
mycin nor was resistance inducible. Four strains were re-
sistant to levofloxacin (22%), and whilst CLSI breakpoints
do not exist for ciprofloxacin, considerably smaller zones of
clearance exist suggesting its activity is much more limited
(20.5 mm (IQR 18–23) vs 18.5 mm (IQR 14–21), p = 0.07.
In addition beta-lactams commonly used in CF with anti-
pseudomonal activity including meropenem (47 mm IQR
42–50) and piperacillin-tazobactam (49.5 mm IQR 43–51),
showed larger zones of clearing than ceftazidime (34 mm
IQR 20–38) although established breakpoints similarly do
not exist, p = <0.001. Tobramycin, with no appreciable
Gram positive activity beyond Staphylococi, showed very
high levels of resistance with zones (<6 mm).
Lung function in the CF patients was compared at
time of Pneumococcus isolation with values at the pre-
ceding and following two routine clinics to determine if
either an acute deterioration or change in disease trajec-
tory occurred as a result of infection (Figure 1). No dif-
ferences were noted in either percent predicted FEV1 or
FVC through periods of pneumococcal infection.
Discussion
Pneumococcus has been well established as a principle
respiratory tract pathogen, predominantly in the pediatric
Table 2 Pneumococcus isolates from 1986–2013 in adult cystic fibrosis patients













PEN LVX AZM CLI
1 1 1986-05-21 N/Ah 107 N/A N/A N/A N/A Y N Y PA non-muc (107),
PA muc (105) Bcc (106), HI (105)
2 2 1994-03-16 6A/B 107 S S S S Y Y Y PA non-muc (105),
PA muc (107) SA (108)
3 3 1992-09-18 N/A 107 S N/A N/A N/A N N/A N SA (108)
4 3 1992-12-16 N/A 108 S N/A N/A N/A Y N/A N SA (108), HI (108)
5 3 1993-03-04 22 107 S S S S N N Y SA (107), HI (108)
6 3 1993-03-05 9A/V 107 S S S S N N Y SA (107), HI (108)
7 4 1993-03-17 6A/B 107 S S S S Y N N PA non-muc (107),
PA muc (107), Bcc (105), EC (105)
8 5 1996-12-04 33A/F 107 S S S S Y N N PA non-muc (106),
PA muc (107)
9 5 2009-04-08 23A 106 S S S S Y N Y PA muc (105)
10 6 1990-01-17 N/A 107 S N/A N/A N/A Y N N CA (107)
11 7 1993-01-06 N/A 107 S N/A N/A N/A Y N N PA non-muc (107),
PA muc (107)
12 8 1995-10-18 23 F 107 S S S S Y Y Y PA non-muc (107),
PA muc (106)
13 8 1995-11-01 23 F 107 S S S S Y Y Y PA non-muc (107),
PA muc (106)
14 9 1996-10-02 38 107 R R S Y Y N PA non-muc (106), SA (106),
CA (105), Asp (105)
15 10 1995-12-20 7B/C 105 S S S S Y Y N PA muc (105)
16 10 1996-07-31 14 104 S S S S Y N N PA muc (106), SA (104)
17 10 1996-08-28 9A/V 105 S R R S Y N N PA muc (107), CA (104)
18 11 1995-11-22 23B 107 R S S S Y N Y PA non-muc (106),
PA muc (107), EC (105)
19 11 1996-02-21 23B 107 S S S S Y N Y PA non-muc (107),
PA muc (107), EC (106)
20 12 2001-08-21 N/A 107 S N/A N/A N/A N N Y OF (107)
21 12 2003-08-20 NTi 106 S R R S Y N N N/A
22 12 2006-07-17 N/A 106 S N/A N/A N/A Y N/A N/A N/A
23 12 2006-07-21 NT 106 S R S S Y N N Cfc (104), HI (106)
24 12 2009-01-05 14 105 S R R S Y N N HI (106)
25 13 2004-06-16 N/A 107 S N/A N/A N/A Y N N PA muc (107)
26 14 2003-11-26 N/A 106 S N/A N/A N/A Y N N SA (106), PA non-muc (104),
PA muc (104), HI (106)
27 15 2013-10-21 NT 106 S R S S N N N PA non-muc (104),
PA muc (106), SA (106)
aRefer to Table 1.
bCapsular serotyping done on recoverable isolates.
cAntibiotic definitions: Penicillin = PEN, Levofloxacin = LVX, Azithromycin = AZM, Clindamycin = CLI, S = Sensitive, R = Resistant
dInfluenza vaccine prior to pneumococcus isolation.
eReduced PFT: pulmonary function tests; as defined by a reduction in reduction in FEV1 by >10% at time of visit compared to baseline FEV1 levels.
fRequirement for antibiotics at time of pneumococcus presentation.
gPA: P. aeruginosa, SA: S. aureus, HI: Haemophilus influenzae, Bcc: Burkholderia cepacia complex, Asp: Aspergillus. sp, EC: E. coli, CA: Candida albicans, Cfc: Citrobacter
freundii complex, OF: oropharyngeal flora.
hN/A: Not available for serotyping or antibiotic susceptibility testing.
iNT: non-typeable serotype but with positive cps internal PCR product control.
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owing to a state of chronic colonization and infection
alongside a dysregulated host immune response [9]. Des-
pite this, Pneumococcus is uncommonly reported in CF,
and little/no information exists on its prevalence and im-
pact in adult CF patients [2]. Herein we identified that
Pneumococcus comprised less than 0.1% of bacterial iso-
lates from a 34-year comprehensive CF biobank where
Pneumococcus was identified using classical microbiology
protocols, affecting <5% of patients. Furthermore, there
were no documented cases of invasive pneumococcal dis-
ease, such meningitis and blood stream infection, during
this time. The extreme uncommon nature of Pneumococ-
cus in this population was unexpected and may reflect
how CF microbiology protocols have been developed and
biased to identify classical pathogens such as S. aureus,
and P. aeruginosa.
In CF, the traditional clinical picture has been of
chronic lower respiratory tract infections with principal
pathogens including P. aeruginosa, S. aureus, and Bur-
kholderia cepacia complex. Recently, the polymicrobial
nature of CF has been demonstrated to comprise of a
variety of microbial species that include Rothia, Prevo-
tella, Klebsiella and members of the Streptococcus genus
[5]. While several members of the streptococci, such as
S. anginosus group, have been implicated in CF disease
progression [6], other viridans group streptococci (VGS)
including S. pneumoniae have not traditionally been
considered as primary CF pathogens. However, when
specifically sought, using a combination of selective
agars such as Mitis–Salivarius agar and high density
sampling low levels of Pneumococcus can be identified
in up to 10% of sputum samples [2]. In this light it is ap-
parent that traditional approaches to CF sputum culture
are likely to be insensitive to the identification of
Pneumococcus, particularly at low density.
As a case series and not a controlled study, limited in-
formation can be inferred regarding risk factors for
Pneumococcus isolation detected by traditional CF pro-
tocols. However, 4/15 patients had chronic infection
with H. influenzae, which is much higher than the stand-
ard colonization frequency observed in the adult CF
population (<10%) [10]. A high prevalence of smokers
similarly was observed, which may explain the dispro-
portionate identification of H. influenzae, a common col-
onizers pathogen in smokers [11]. Furthermore, a large
proportion of colonization events were preceded by viral
upper respiratory tract infection, which in the general
population result in increased colonization potential of
these Pneumococcus [12].
The clinical impact of Pneumococcus in CF is poorly
understood. We sought specifically to determine if either
an acute, or long-term impact followed detection of
Pneumococcus from a CF sputum sample using classicalCF protocols. We did not identify any statistical differ-
ence in lung function at time of isolation compared to
the two clinic visits occurring before or after pneumo-
coccal isolation as measured by FEV1 and FVC. Further-
more, patients with Pneumococcus in their sputum were
no more likely to require antibiotics than during clinic
visits occurring in the two years before or after. Finally,
no patient went on to develop persistent chronic infec-
tion, suggesting that eradication strategies advocated for
pathogens such as P. aeruginosa, MRSA are not war-
ranted [13,14].
Antibiotic resistance is a growing concern within CF
patients, given the longer life expectancy and increased
demand on antibiotic use. S. pneumoniae is readily com-
petent, allowing horizontal gene transfer between micro-
organisms for several antibiotic resistance markers
including pbp1a, pbp2, mefE, ermAM and tetM [15].
The presence of S. pneumoniae may not be overtly
pathogenic in a traditional sense within the CF patient,
but may be contributing to the greater antibiotic resis-
tome of the patient by dissemination of antibiotic resist-
ance markers. Antibiotic resistance has been observed in
other streptococci species in CF, in particular the S.
anginosus group, azithromycin (54.9%), erythromycin
(52.9%) and clindamycin (49.0%) [16]. While susceptibil-
ity data in our study suggests limited resistance to several
classes of antibiotics, the Pneumococcal resistance rates
have been reported to be on the rise by other groups with
73% to penicillin, 42% to erythromycin, 58% to tetracycline
and 67% to trimethoprim-sulfamethoxazole [1]. The dis-
crepancy in Pneumococcus susceptibility values in CF
may be attributed to therapeutic management at various
sites, global trends of antibiotic use and resistance, and ex-
posure to agents from the pediatric to adult clinics.
Serotyping in this study identified ten different capsular
serotypes with no predominant pattern observed. Another
work assessing Pneumococcus population structure found
the most frequent serotypes in CF were 23 F, 19 F, 6A and
6B [1]. Geographical location and time period may in part
affect serotype distribution, as has been described with
several antibiotic resistance mechanisms in Pneumococcus
[17]. Interestingly, the 23-valent-Pneumococcus vaccine
does not cover serotypes 38 and 23A, which were identi-
fied in several of our patients. The variety of serotypes
within the same patient suggests, given the short time
frame between some repeated cultures, likely several
strains of pneumococci were present but with only a single
isolate recognized as opposed to strain displacement
within a single patient. Indeed, co-colonization has been
observed with surprising frequency [18]. Coinciding with
this, strain displacement of serotypes may be occurring
over prolonged periods of time. Furthermore, several iso-
lates could not be serotyped using a strategy to detect the
most common capsular serotypes [7], which may suggest
Figure 1 (See legend on next page.)
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Figure 1 Pulmonary function (FEV1 and FVC) among CF patients with Pneumococcus. Spirometery was compared from each patient at each time of
Pneumococcal isolation with the values from two clinics immediately preceding and following this visit to assess for impact on lung function. No
changes in FEV1 were apparent at the time of pneumococcus infection compared to prior (p = 0.6665) or subsequent clinic visits (p = 0.4783).
Furthermore, no differences in FVC were observed at time of pneumococcus colonization relative to prior values (p = 0.3354) or follow-up (p = 0.5385).
Overall, there appeared to be no significant impact on lung function.
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investigation.
The question as to why Pneumococcus was observed in
such low prevalence is of particular interest. This may in
part be due to in sensitive differentiation from other VGS
using standard practice of bile solubility, optochin suscep-
tibility and colony morphology [19]. Furthermore, the use
of primarily quantitative microbiology may also result in
reduced identification of low quantity organisms within
cultures. As well, Pneumococcus colonization is typically
higher in young children and then declines with age with
a peak in the elderly age group – a group not represented
in an adult CF clinic [20]. The median predicted survival
of CF patients in Canada is current 50.9 years [21] and as
this population ages, Pneumococcal disease may become
an issue for older CF patients [22]. More provocatively,
however, it may be that chronic infection with classical CF
respiratory pathogens and the resultant competition for
space and nutrients in the lower airways is protective
against extrinsic pathogens such as S. pneumoniae.
Current recommendations in CF care involve pneumo-
coccus vaccination with either the 23-valent polysaccharide
or, 7 or 13-valent conjugate vaccine [23,24]. The recom-
mendations for these guidelines are derived from those
with other respiratory diseases. As such, the need for pre-
vention and treatment of Pneumococcus in CF warrants
further investigation as work from this study has shown
both low incidence of culture and recovery of patients with-
out further clinical decline, spontaneous clearance and lack
of chronic infection. Furthermore, the 23-valent vaccine
does not reduce rates of pneumonia but rather is effective
in preventing invasive disease such as meningitis and
bacteremia [25]. The role of vaccination in CF patients is
one that warrants further exploration and perhaps recom-
mendations based on CF specific data as opposed to adap-
tion of recommendations for those with other types of
chronic lung disease.
This study has several notable limitations. Few patients
were included, and patient data was also limited for those
patients who are lost to follow-up or deceased. As we fo-
cused on short-term outcomes in this small population we
may have been insensitive to longer-term effects. Other
clinical parameters may be used in the future to assess if
Pneumococcus isolation in CF patients affects disease pro-
gression such as number of exacerbations per year, number
of hospitalizations, changes in antibiotic regimen and qual-
ity of life index scores [26]. As this was a retrospective studyevaluating the isolation of S. pneumoniae using traditional
CF microbiology protocols, it is likely insensitive to the
identification of isolates present at low levels. Indeed, pro-
spective studies using semi-selective medias and in depth
culturing would be required to determine the prevalence of
low level colonization, and how this might impact clinical
progression. Furthermore, it may be necessary to adjunct
phenotypic culturing with molecular methods as this has
been shown to improve efficacy of identification [27].
Conclusions
In this study, we found Pneumococcus was infrequently
identified in the respiratory tract of adults with CF. Fur-
thermore, when Pneumococcus was identified, no appar-
ent adverse impact on outcomes was noted with respect
to requirement for rescue antibiotic therapy or changes
in lung function.
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